High court ruling on gene patents lifts Myriad

June 13, 2013 by The Associated Press

Shares of diagnostic test maker Myriad Genetics Inc. are jumping Thursday after the Supreme Court issued a mixed ruling in a case involving the company's patents on genes at the center of its tests for increased risk of breast and ovarian cancer.

Myriad, based in Salt Lake City, sells a popular test for a gene linked to —the only one available because of its patents.

The high court ruled that genes naturally found in the body cannot be patented, but that synthetically created genetic material can be patented. That leaves an opening for Myriad to continue making money, Justice Clarence Thomas wrote in the court's majority opinion.

Myriad shares were up 10.3 percent, or $3.48, at to $37.40. They had earlier set a 52-week high at $38.27.

Explore further: US court to decide if human genes can be patented

Related Stories

US court to decide if human genes can be patented

November 30, 2012

The Supreme Court announced Friday it will decide whether companies can patent human genes, a decision that could reshape medical research in the United States and the fight against diseases like breast and ovarian cancer.

Recommended for you

IROS 2015: Thermobot feels the heat and walks (and walks)

October 7, 2015

Takeru Nemoto and Akio Yamamoto of University of Tokyo have presented a bipedal walking robot which is driven by constant heating. No sensors. No actuators, said Even Ackerman in IEEE Spectrum. Just a hot surface will do ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.